ARQT

Arcutis Biotherapeutics

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/05/26

Business Summary

AMETEK generates cash by manufacturing highly engineered instruments and electromechanical devices that are deeply embedded in customer workflows. Its moat is built on precision, reliability, and switching costs—once its equipment is qualified inside industrial systems, replacement risk drops materially. The company benefits from niche market leadership across multiple specialized product categories, allowing pricing power that supports its 13.90% operating margin. Recurring demand from maintenance, calibration, and system upgrades further stabilizes cash generation across cycles.

VALUATION

P/E

-

Market Cap ($M USD)

$3,002

Forward P/E

18.9

PEG

1.5

PRICE TO SALES

8.2

PRICE TO BOOK

15.9

EV / EBITDA

1627.00

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.13

Next Year EPS Growth Estimate

$1.28

Next Year Revenue Growth Estimate

29.90%

Return on Equity (ROE)

-8.50%

Operating Margin

-3.20%

Debt-to-Equity

0.6

Piotroski F-Score

5

Altman Z-Score

5.3

Return on Invested Capital (ROIC)

-4.80%%

Current Ratio

3.2

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 36.8x earnings and 26.9x forward earnings, AME is priced as a premium compounder, not an industrial cyclical. The forward multiple implies confidence in durability, yet the 6.1 PEG ratio suggests investors are paying aggressively relative to growth. Financially, the balance sheet is fortress-like with an Altman Z-Score of 7.9 and a manageable 25.80% Debt/Equity ratio, signaling very low bankruptcy risk. This is not a distressed opportunity; it is a high-quality industrial trading at a full valuation, where upside depends on sustained execution rather than multiple expansion.

AI Exposure / Tech Reliance

As a Specialty Industrial Machinery company, AME operates in a segment that benefits directly from automation, precision instrumentation, and digitization trends. Industrial modernization and AI-driven process optimization increase demand for high-spec equipment and monitoring systems. Its positioning within Industrials provides structural exposure to capital investment cycles tied to advanced manufacturing.

The Bull Case

A GARP investor buys this for capital efficiency and durability. A 12.50% ROIC comfortably above typical capital costs, combined with a 13.90% operating margin, signals disciplined operations in a capital-intensive sector. The Piotroski F-Score of 6 indicates stable financial health without distress signals, while a 5.50% Return on Equity shows profitability without excessive leverage given Debt/Equity at 25.80%. With a strong Altman Z-Score of 7.9 and institutional ownership at 251.59, this is clearly an institutionally endorsed compounder with balance sheet strength and consistent profitability metrics that justify a premium bias.

The Bear Case

The problem is valuation versus growth. A PEG of 6.1 is extreme, implying growth expectations that may not align with a 13.90% operating margin business in an industrial sector. Short interest at 11.20% of float is not trivial, suggesting a meaningful cohort is betting against the sustainability of current pricing. Add in a thin 0.2 yield and a modest current ratio of 1.1, and investors are taking cyclical exposure without meaningful income protection or liquidity cushion, all while paying 36.8x earnings.

Market Sentiment & Smart Money

Short Interest %

15.60%

Analyst Consensus

1.56

Average Analyst Price Target

$34.75

Institutional Ownership %

108.70%

1-Year Beta

1.2

Insider Buying % (6 Mo)

1.70%%

Distance to 52-Week High

76.20%%

Distance to 52-Week Low

204.10%%